Oxford Vaccine Candidate Looks Promising as Older People Show Strong Immune Response

In this handout photo released by the University of Oxford, a volunteer participates in the CCP virus vaccine trial in Oxford, England, on July 7, 2020. The Canadian Press/AP-University of Oxford via AP

A vaccine under development has shown promise due to its producing a good immune response and low side effects in older people who are among those most vulnerable to the CCP virus.

The vaccine candidate, AZD1222, is being developed by Oxford University in partnership with the Cambridge based pharmaceutical giant, AstraZeneca.